Imunon, Inc. (IMNN)

Market Cap	11.67M
Revenue (ttm)	n/a
Net Income (ttm)	-14.33M
Shares Out	3.07M
EPS (ttm)	-9.54
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,360
Open	3.720
Previous Close	3.750
Day's Range	3.651 - 3.886
52-Week Range	3.560 - 41.217
Beta	1.93
Analysts	Buy
Price Target	182.61 (+4,705.53%)
Earnings Date	Nov 13, 2025

About IMNN

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 5, 1985
• Employees: 25
• Stock Exchange: NASDAQ
• Ticker Symbol: IMNN
• Website: https://imunon.com

Analyst Summary

According to 2 analysts, the average rating for IMNN stock is "Buy." The 12-month stock price target is $182.61, which is an increase of 4,705.53% from the latest price.

Price Target

$182.61

(4,705.53% upside)

Analyst Consensus: Buy